Here's the question and answer session that followed the presentations by Drs.

Here's the second presentation from our program on "Immunotherapies for Lung Cancer: Can We Deliver on the Promise?".  Our

Here's part 1 of the podcast with Dr. Ramaswamy Govindan from Washington University, in St. Louis, and Dr. Julie Brahmer from Johns Hopkins University in Baltimore, splitting the big topic of new developments in immunotherapy for lung cancer.

The annual conference of the American Society of Clinical Oncology in late spring is the biggest event in the cancer world, where more of the big trials are presented than at any other time all year.  In the lung cancer world, it’s looking like this one won’t be a blockbuster but will have some promising and interesting findings to dis

The epidermal growth factor receptor (EGFR) is a central component of a cell pathway for growth and cell division that is thought to be affected in many cancers, including NSCLC. EGFR inhibitors have been the focus of clinical trials for several years and are now used for many types of cancer.

Immune-based approaches in lung cancer tend to generate significant buzz among patients and the general public, as well as in the media, but not as much optimism within the oncology world. Much of that is for good reason: while the concept of a minimally toxic, long-lasting anti-cancer approach like a vaccine is very appealing to all of us, oncologists have seen many hyped immune-based therapies deliver far less than their promise. This is for several reasons.